IS2186B - Ísómerísk sambrædd pýrrólókarbasól og ísóindólón - Google Patents

Ísómerísk sambrædd pýrrólókarbasól og ísóindólón

Info

Publication number: IS2186B
Authority: IS; Iceland
Prior art keywords: isoindolone; fused pyrrolocarbazole; isomeric fused; directed; same
Prior art date: 1999-08-20

Application number

IS6266A

Other languages

English (en)

Other versions

IS6266A (is

Inventor

L. Hudkins Robert

Original Assignee

Cephalon, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-20

Filing date

2002-02-12

Publication date

2006-12-15

2002-02-12 Application filed by Cephalon, Inc. filed Critical Cephalon, Inc.

2002-02-12 Publication of IS6266A publication Critical patent/IS6266A/is

2006-12-15 Publication of IS2186B publication Critical patent/IS2186B/is

Links

XTBAPWCYTNCZTO-UHFFFAOYSA-N 1H-isoindolone Natural products C1=CC=C2C(=O)N=CC2=C1 XTBAPWCYTNCZTO-UHFFFAOYSA-N 0.000 title abstract 3
QNMMYUBZGLXCCK-UHFFFAOYSA-N pyrrolo[3,2-a]carbazole Chemical compound N1=C2C=CC=CC2=C2C1=C1C=CN=C1C=C2 QNMMYUBZGLXCCK-UHFFFAOYSA-N 0.000 title abstract 2
238000000034 method Methods 0.000 abstract 2
238000009007 Diagnostic Kit Methods 0.000 abstract 1
238000003556 assay Methods 0.000 abstract 1
239000003153 chemical reaction reagent Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Reproductive Health (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Pyrrole Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Indole Compounds (AREA)

IS6266A 1999-08-20 2002-02-12 Ísómerísk sambrædd pýrrólókarbasól og ísóindólón IS2186B (is)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US15036799P	1999-08-20	1999-08-20
US09/640,825 US6399780B1 (en)	1999-08-20	2000-08-17	Isomeric fused pyrrolocarbazoles and isoindolones
PCT/US2000/022724 WO2001014380A1 (en)	1999-08-20	2000-08-18	Isomeric fused pyrrolocarbazoles and isoindolones

Publications (2)

Publication Number	Publication Date
IS6266A IS6266A (is)	2002-02-12
IS2186B true IS2186B (is)	2006-12-15

Family

ID=26847579

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS6266A IS2186B (is)	1999-08-20	2002-02-12	Ísómerísk sambrædd pýrrólókarbasól og ísóindólón

Country Status (26)

Country	Link
US (4)	US6399780B1 (is)
EP (1)	EP1206473B1 (is)
JP (1)	JP4776842B2 (is)
KR (1)	KR100756686B1 (is)
CN (1)	CN1370173A (is)
AT (1)	ATE280172T1 (is)
AU (1)	AU776475C (is)
BG (1)	BG65545B1 (is)
BR (1)	BR0013811A (is)
CA (1)	CA2381885C (is)
CZ (1)	CZ2002616A3 (is)
DE (1)	DE60015153T2 (is)
EA (1)	EA005920B1 (is)
ES (1)	ES2230140T3 (is)
HK (1)	HK1046904B (is)
HU (1)	HUP0202758A3 (is)
IL (2)	IL148180A0 (is)
IS (1)	IS2186B (is)
MX (1)	MXPA02001789A (is)
NO (1)	NO323375B1 (is)
NZ (1)	NZ517174A (is)
PL (1)	PL354180A1 (is)
PT (1)	PT1206473E (is)
SK (1)	SK286805B6 (is)
TR (1)	TR200200474T2 (is)
WO (1)	WO2001014380A1 (is)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6399780B1 (en) *	1999-08-20	2002-06-04	Cephalon, Inc.	Isomeric fused pyrrolocarbazoles and isoindolones
US7122679B2 (en) *	2000-05-09	2006-10-17	Cephalon, Inc.	Multicyclic compounds and the use thereof
AR035971A1 (es) *	2001-05-16	2004-07-28	Cephalon Inc	Metodos para el tratamiento y la prevencion del dolor
EP1436279B8 (en) *	2001-09-21	2008-10-29	Smithkline Beecham Corporation	Chemical compounds
SE0104140D0 (sv) *	2001-12-07	2001-12-07	Astrazeneca Ab	Novel Compounds
UA80447C2 (en) *	2002-10-08	2007-09-25		Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US7255860B2 (en) *	2002-10-08	2007-08-14	Rinat Neuroscience Corp.	Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
EP1556083B1 (en)	2002-10-08	2011-02-02	Rinat Neuroscience Corp.	Methods for treating post-surgical pain by admisnistering an antibody against nerve growth factor and compositions containing the same
US7569364B2 (en) *	2002-12-24	2009-08-04	Pfizer Inc.	Anti-NGF antibodies and methods using same
EP2270048B1 (en) *	2002-12-24	2015-11-11	Rinat Neuroscience Corp.	Anti-NGF antibodies and methods using same
US9498530B2 (en)	2002-12-24	2016-11-22	Rinat Neuroscience Corp.	Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
KR20050111598A (ko)	2003-02-19	2005-11-25	리나트 뉴로사이언스 코퍼레이션	신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물
US7169802B2 (en)	2003-12-23	2007-01-30	Cephalon, Inc.	Fused pyrrolocarbazoles
AU2005243247B2 (en) *	2004-04-07	2012-03-01	Regents Of The University Of Minnesota	Methods for treating bone cancer pain by administering a nerve growth factor antagonist
US20060058250A1 (en) *	2004-09-10	2006-03-16	Cephalon, Inc.	Methods of treating proliferative skin diseases using carbazole derivatives
WO2006034121A1 (en) *	2004-09-17	2006-03-30	Henry Ford Health System	Methods and compositions for use of angiogenesis inhibitors in the prevention and/or control of epilepsy
PL2383268T3 (pl)	2005-02-04	2016-02-29	Astrazeneca Ab	Pochodne pirazoliloaminopirydyny użyteczne jako inhibitory kinazy
PT1853588E (pt) *	2005-02-16	2008-08-25	Astrazeneca Ab	Compostos químicos
WO2006087538A1 (en) *	2005-02-16	2006-08-24	Astrazeneca Ab	Chemical compounds
JP2008540622A (ja) *	2005-05-16	2008-11-20	アストラゼネカアクチボラグ	化合物
WO2007049041A1 (en)	2005-10-28	2007-05-03	Astrazeneca Ab	4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
WO2007123269A1 (ja)	2006-04-19	2007-11-01	Astellas Pharma Inc.	アゾールカルボキサミド誘導体
US20080021013A1 (en) *	2006-07-21	2008-01-24	Cephalon, Inc.	JAK inhibitors for treatment of myeloproliferative disorders
US20090326229A1 (en) *	2006-08-02	2009-12-31	Takeda Phamaceutical Company Limited	Alpha-carboline derivatives and methods for preparation thereof
EP2081892A4 (en) *	2006-11-17	2014-03-05	Donald F Weaver	COMPOUNDS AND METHOD FOR THE TREATMENT OF PROTEIN DISAPPEARANCE
WO2010131855A2 (ko)	2009-05-13	2010-11-18	덕산하이메탈(주)	오원자 헤테로고리를 포함하는 화합물 및 이를 이용한 유기전기소자, 그 단말
WO2008129255A1 (en) *	2007-04-18	2008-10-30	Astrazeneca Ab	5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer
UA99459C2 (en) *	2007-05-04	2012-08-27	Астразенека Аб	9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
US20100137398A1 (en) *	2007-05-04	2010-06-03	Novartis Ag	Use of hdac inhibitors for the treatment of gastrointestinal cancers
RU2461551C2 (ru)	2007-10-24	2012-09-20	Астеллас Фарма Инк.	Азолкарбоксамидное соединение или его фармацевтически приемлемая соль
US8426673B2 (en)	2008-01-11	2013-04-23	Astellas Pharma, Inc.	Pathological animal model for pelvic pain syndrome
UY31885A (es) *	2008-06-11	2010-01-29	Astrazeneca Ab	Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
RU2011116928A (ru) *	2008-09-30	2012-11-20	Астразенека Аб (Se)	Гетероциклические ингибиторы jак киназы
WO2010059795A1 (en)	2008-11-19	2010-05-27	Cephalon, Inc.	Novel forms of an indazolo [5,4-a] pyrrolo [3,4-c] carbazole compound
EP2415773B1 (en) *	2009-03-30	2016-02-17	Duk San Neolux Co., Ltd.	Organic electronic device, compounds for same, and terminal
WO2012024650A2 (en)	2010-08-19	2012-02-23	Abbott Laboratories	Anti-ngf antibodies and their use
KR101497122B1 (ko) *	2011-08-09	2015-03-06	덕산네오룩스 주식회사	2개 이상의 오원자 헤테로고리를 포함하는 화합물 및 이를 이용한 유기전기소자, 그 단말
TWI585088B (zh)	2012-06-04	2017-06-01	第一三共股份有限公司	作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
JP6629069B2 (ja)	2012-06-06	2020-01-15	ゾエティス・エルエルシー	イヌ化抗ｎｇｆ抗体およびその方法
KR101478884B1 (ko)	2012-12-24	2015-01-05	충남대학교산학협력단	비스인돌일말레이미드계 화합물 및 이의 제조방법
KR20200090198A (ko)	2017-11-23	2020-07-28	바이오메드 엑스 게엠베하	트로포미오신 수용체 키나제 A(TrkA) 저해제로서의 피리미딘 유도체
MX2020009526A (es)	2018-03-12	2020-10-28	Zoetis Services Llc	Anticuerpos anti-ngf y metodos de estos.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816450A (en)	1986-09-15	1989-03-28	Duke University	Inhibition of protein kinase C by long-chain bases
US4735939A (en)	1987-02-27	1988-04-05	The Dow Chemical Company	Insecticidal activity of staurosporine
US4923986A (en)	1987-03-09	1990-05-08	Kyowa Hakko Kogyo Co., Ltd.	Derivatives of physiologically active substance K-252
JPH07113027B2 (ja)	1987-12-24	1995-12-06	協和醗酵工業株式会社	Ｋ−２５２誘導体
FR2631199B1 (fr)	1988-05-09	1991-03-15	Centre Nat Rech Scient	Reacteur a plasma
US5621101A (en)	1992-07-24	1997-04-15	Cephalon, Inc.	Protein kinase inhibitors for treatment of neurological disorders
EP0699204B1 (en)	1993-05-28	1998-04-15	Cephalon, Inc.	Use of indolocarbazole derivatives to treat a pathological condition of the prostate
US5624949A (en)	1993-12-07	1997-04-29	Eli Lilly And Company	Protein kinase C inhibitors
US5545636A (en)	1993-12-23	1996-08-13	Eli Lilly And Company	Protein kinase C inhibitors
DK0817627T3 (da)	1993-12-23	2005-06-06	Lilly Co Eli	Inhibitorer af proteinkinase C
GB9416467D0 (en) *	1994-08-13	1994-10-05	Wellcome Found	Compounds for use in medicine
US5594009A (en) *	1994-10-14	1997-01-14	Cephalon, Inc.	Fused pyrrolocarbazoles
US5591855A (en) *	1994-10-14	1997-01-07	Cephalon, Inc.	Fused pyrrolocarbazoles
US5705511A (en) *	1994-10-14	1998-01-06	Cephalon, Inc.	Fused pyrrolocarbazoles
US5475110A (en) *	1994-10-14	1995-12-12	Cephalon, Inc.	Fused Pyrrolocarbazoles
CA2237221C (en)	1995-11-20	2003-03-25	Eli Lilly And Company	Protein kinase c inhibitor
US5808060A (en) *	1995-12-11	1998-09-15	Cephalon, Inc.	Fused isoindolones
US5616724A (en) *	1996-02-21	1997-04-01	Cephalon, Inc.	Fused pyrrolo[2,3-c]carbazole-6-ones
JP2000516250A (ja)	1996-08-22	2000-12-05	ブリストルーマイヤーズスクイブカンパニー	インドロピロロカルバゾールの細胞毒性アミノ糖および関連する糖誘導体
US6399780B1 (en) *	1999-08-20	2002-06-04	Cephalon, Inc.	Isomeric fused pyrrolocarbazoles and isoindolones

2000
- 2000-08-17 US US09/640,825 patent/US6399780B1/en not_active Expired - Lifetime
- 2000-08-18 AU AU66471/00A patent/AU776475C/en not_active Ceased
- 2000-08-18 PT PT00954136T patent/PT1206473E/pt unknown
- 2000-08-18 WO PCT/US2000/022724 patent/WO2001014380A1/en not_active Ceased
- 2000-08-18 EA EA200200271A patent/EA005920B1/ru not_active IP Right Cessation
- 2000-08-18 SK SK246-2002A patent/SK286805B6/sk not_active IP Right Cessation
- 2000-08-18 CA CA002381885A patent/CA2381885C/en not_active Expired - Fee Related
- 2000-08-18 BR BR0013811-8A patent/BR0013811A/pt not_active Application Discontinuation
- 2000-08-18 NZ NZ517174A patent/NZ517174A/en unknown
- 2000-08-18 EP EP00954136A patent/EP1206473B1/en not_active Expired - Lifetime
- 2000-08-18 JP JP2001518711A patent/JP4776842B2/ja not_active Expired - Fee Related
- 2000-08-18 AT AT00954136T patent/ATE280172T1/de active
- 2000-08-18 DE DE60015153T patent/DE60015153T2/de not_active Expired - Lifetime
- 2000-08-18 KR KR1020027002117A patent/KR100756686B1/ko not_active Expired - Fee Related
- 2000-08-18 HK HK02108409.6A patent/HK1046904B/en not_active IP Right Cessation
- 2000-08-18 CZ CZ2002616A patent/CZ2002616A3/cs unknown
- 2000-08-18 ES ES00954136T patent/ES2230140T3/es not_active Expired - Lifetime
- 2000-08-18 MX MXPA02001789A patent/MXPA02001789A/es active IP Right Grant
- 2000-08-18 CN CN00811850A patent/CN1370173A/zh active Pending
- 2000-08-18 PL PL00354180A patent/PL354180A1/xx unknown
- 2000-08-18 HU HU0202758A patent/HUP0202758A3/hu unknown
- 2000-08-18 IL IL14818000A patent/IL148180A0/xx active IP Right Grant
- 2000-08-18 TR TR2002/00474T patent/TR200200474T2/xx unknown
2002
- 2002-02-01 US US10/062,159 patent/US6635669B2/en not_active Expired - Lifetime
- 2002-02-12 IS IS6266A patent/IS2186B/is unknown
- 2002-02-14 IL IL148180A patent/IL148180A/en not_active IP Right Cessation
- 2002-02-19 NO NO20020809A patent/NO323375B1/no not_active IP Right Cessation
- 2002-02-21 BG BG106423A patent/BG65545B1/bg unknown
2003
- 2003-04-24 US US10/422,164 patent/US6872746B2/en not_active Expired - Fee Related
2005
- 2005-01-05 US US11/029,330 patent/US7291732B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
NO20020809D0 (no)	2002-02-19
PL354180A1 (en)	2003-12-29
US20030216419A1 (en)	2003-11-20
HK1046904B (en)	2005-05-06
US6399780B1 (en)	2002-06-04
KR20020038730A (ko)	2002-05-23
US6635669B2 (en)	2003-10-21
JP2003507480A (ja)	2003-02-25
BG65545B1 (bg)	2008-11-28
ES2230140T3 (es)	2005-05-01
US20050107458A1 (en)	2005-05-19
IL148180A (en)	2008-04-13
EP1206473B1 (en)	2004-10-20
CN1370173A (zh)	2002-09-18
NZ517174A (en)	2003-09-26
CA2381885C (en)	2009-10-27
AU6647100A (en)	2001-03-19
US6872746B2 (en)	2005-03-29
AU776475C (en)	2005-04-07
US20020147341A1 (en)	2002-10-10
NO20020809L (no)	2002-02-20
EA005920B1 (ru)	2005-08-25
NO323375B1 (no)	2007-04-16
BR0013811A (pt)	2002-07-23
ATE280172T1 (de)	2004-11-15
SK286805B6 (sk)	2009-05-07
BG106423A (en)	2002-09-30
HUP0202758A2 (hu)	2002-12-28
HUP0202758A3 (en)	2004-12-28
SK2462002A3 (en)	2002-12-03
PT1206473E (pt)	2005-01-31
WO2001014380A1 (en)	2001-03-01
CZ2002616A3 (cs)	2003-04-16
AU776475B2 (en)	2004-09-09
EA200200271A1 (ru)	2002-08-29
US7291732B2 (en)	2007-11-06
EP1206473A1 (en)	2002-05-22
KR100756686B1 (ko)	2007-09-07
DE60015153T2 (de)	2006-02-09
MXPA02001789A (es)	2003-07-14
IL148180A0 (en)	2002-09-12
TR200200474T2 (tr)	2002-06-21
IS6266A (is)	2002-02-12
DE60015153D1 (de)	2004-11-25
CA2381885A1 (en)	2001-03-01
HK1046904A1 (en)	2003-01-30
JP4776842B2 (ja)	2011-09-21

Publication	Publication Date	Title
IS6266A (is)	2002-02-12	Ísómerísk sambrædd pýrrólókarbazól og ísóindólón
MXPA02004415A (es)	2004-09-10	Pirazolonas sustituidas con heterociclicas.
EA200100589A1 (ru)	2002-02-28	Азабициклоалканы как модуляторы ccr5
HUP0203567A2 (hu)	2003-02-28	APRIL-receptor (BCMA) és alkalmazásai
EA200100588A1 (ru)	2002-02-28	Пиперидины как модуляторы ccr5
ES2195163T3 (es)	2003-12-01	Derivados de pirimidina biciclicos y su uso como anticoagulantes.
EA200000298A1 (ru)	2000-10-30	Агонисты простагландинов и их применение для лечения заболеваний костей
DE60107687D1 (de)	2005-01-13	Cyclpentanoindole, mischungen derartige verbindungen enthaltend und behandlungsmethoden
FI964520L (fi)	1996-11-11	Atsabisykloyhdisteet
DK1083903T3 (da)	2005-01-03	Brobundne indenopyrrolocarbazoler
EA200100887A1 (ru)	2002-02-28	Циклические замещенные конденсированные пирролкарбазолы и изоиндолоны
EE05091B1 (et)	2008-10-15	Oligosahhariidid, nende valmistamismeetod ja kasutamine ning farmatseutilised kompositsioonid
MY158159A (en)	2016-09-15	Novel fused pyrrolocarbazoles
TR200002380T2 (tr)	2001-03-21	Yeni triazolo (4,5-d) pirimidin bileşikleri
SG149042A1 (en)	2009-01-29	Novel fused pyrrolocarbazoles
EA200300579A1 (ru)	2003-12-25	Соединение лактама
YU62504A (sh)	2006-08-17	Triciklična 2-pirimidonska jedinjenja korisna kao inhibitori hiv reverzne transkriptoze
EE200200326A (et)	2003-10-15	Asendatud homopiperidüülbensimidasooli analoog, meetod selle valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
SE9902551D0 (sv)	1999-07-02	Novel compounds
ES2195033T3 (es)	2003-12-01	Iso-indolonas condensadas utilizadas como inhibidores de proteina quinasa c.
EA199700223A1 (ru)	1998-04-30	Бициклические антагонисты тахикининов, их получение и применение в фармацевтической композиции
EA200200981A1 (ru)	2003-02-27	Антагонисты рецептора il-8
ATE281455T1 (de)	2004-11-15	Oxindolderivate
ATE244714T1 (de)	2003-07-15	1-(3-aminoindazol-5-yl)-3-phenylmethyl cyclische harnstoffe und ihre verwendung als hiv protease inhibitoren